CryoPort, Inc. $CYRX Shares Acquired by UBS Group AG

UBS Group AG grew its position in CryoPort, Inc. (NASDAQ:CYRX) by 6.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,421,884 shares of the company’s stock after acquiring an additional 90,363 shares during the period. UBS Group AG’s holdings in CryoPort were worth $13,650,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of CYRX. Mak Capital One LLC acquired a new position in shares of CryoPort in the third quarter worth about $7,756,000. Millennium Management LLC raised its stake in shares of CryoPort by 18.5% during the 3rd quarter. Millennium Management LLC now owns 2,620,906 shares of the company’s stock worth $24,846,000 after buying an additional 408,335 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of CryoPort by 283.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock worth $4,970,000 after buying an additional 387,440 shares during the period. AQR Capital Management LLC raised its stake in shares of CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after buying an additional 194,482 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of CryoPort by 31.1% during the 3rd quarter. Bank of America Corp DE now owns 521,140 shares of the company’s stock worth $4,940,000 after buying an additional 123,719 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insider Buying and Selling at CryoPort

In other CryoPort news, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider owned 103,697 shares in the company, valued at approximately $829,576. This represents a 3.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $63,344.00. Following the completion of the sale, the chief executive officer owned 1,054,501 shares of the company’s stock, valued at approximately $8,436,008. The trade was a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 59,939 shares of company stock worth $471,183. Insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

CYRX has been the subject of several research analyst reports. Guggenheim upped their target price on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday. Craig Hallum started coverage on shares of CryoPort in a research report on Monday, March 30th. They set a “buy” rating and a $15.00 price target for the company. Finally, Needham & Company LLC upped their price target on shares of CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, CryoPort has an average rating of “Moderate Buy” and an average price target of $14.44.

CryoPort Stock Performance

NASDAQ CYRX opened at $13.23 on Friday. The business has a fifty day moving average price of $9.66 and a 200 day moving average price of $9.47. CryoPort, Inc. has a one year low of $5.31 and a one year high of $13.79. The company has a market cap of $666.79 million, a P/E ratio of 9.80 and a beta of 1.75.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The firm had revenue of $47.80 million during the quarter, compared to analyst estimates of $44.86 million. As a group, sell-side analysts predict that CryoPort, Inc. will post -0.74 EPS for the current fiscal year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.